BNP Paribas Financial Markets Raises Stock Position in Chemed Corporation $CHE

BNP Paribas Financial Markets lifted its position in Chemed Corporation (NYSE:CHE) by 14.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 35,024 shares of the company’s stock after buying an additional 4,430 shares during the period. BNP Paribas Financial Markets’ holdings in Chemed were worth $14,985,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of CHE. Geneos Wealth Management Inc. grew its position in shares of Chemed by 330.4% in the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock worth $61,000 after buying an additional 76 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in shares of Chemed by 67.0% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 11,365 shares of the company’s stock worth $5,534,000 after buying an additional 4,560 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Chemed in the 2nd quarter worth approximately $579,000. Brown Advisory Inc. grew its position in shares of Chemed by 36.9% in the 2nd quarter. Brown Advisory Inc. now owns 549 shares of the company’s stock worth $267,000 after buying an additional 148 shares during the last quarter. Finally, Cerity Partners LLC grew its position in shares of Chemed by 237.7% in the 2nd quarter. Cerity Partners LLC now owns 4,451 shares of the company’s stock worth $2,165,000 after buying an additional 3,133 shares during the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.

Chemed Stock Up 1.9%

NYSE:CHE opened at $440.67 on Friday. The company has a current ratio of 0.85, a quick ratio of 0.83 and a debt-to-equity ratio of 0.11. Chemed Corporation has a twelve month low of $365.20 and a twelve month high of $565.66. The company’s 50 day moving average is $409.41 and its two-hundred day moving average is $424.56. The company has a market cap of $5.85 billion, a PE ratio of 24.01, a P/E/G ratio of 1.66 and a beta of 0.54.

Chemed (NYSE:CHE) last announced its quarterly earnings data on Thursday, April 23rd. The company reported $5.65 EPS for the quarter, beating the consensus estimate of $5.30 by $0.35. Chemed had a net margin of 10.23% and a return on equity of 27.18%. The business had revenue of $657.51 million during the quarter, compared to analysts’ expectations of $659.22 million. During the same period in the previous year, the business posted $5.63 EPS. The business’s quarterly revenue was up 1.6% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. Analysts anticipate that Chemed Corporation will post 22.3 EPS for the current year.

Chemed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 16th. Shareholders of record on Thursday, May 28th will be paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.5%. The ex-dividend date is Thursday, May 28th. Chemed’s payout ratio is presently 13.08%.

Insider Buying and Selling

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $421.13, for a total transaction of $842,260.00. Following the completion of the sale, the chief executive officer directly owned 90,219 shares in the company, valued at approximately $37,993,927.47. The trade was a 2.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 3.33% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Royal Bank Of Canada lifted their price objective on shares of Chemed from $422.00 to $436.00 and gave the stock a “sector perform” rating in a research report on Monday, April 27th. Oppenheimer dropped their target price on shares of Chemed from $580.00 to $500.00 and set an “outperform” rating on the stock in a research report on Friday, February 27th. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings raised shares of Chemed from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Finally, Wall Street Zen raised shares of Chemed from a “hold” rating to a “buy” rating in a research report on Sunday, May 31st. Two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Chemed presently has a consensus rating of “Hold” and an average price target of $501.50.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.